Oslo, Norway - 2025.06.27 - Navamedic announces that the Swedish Medical
Products Agency, acting as the Reference Member State, together with the
Concerned Member States in 9 additional countries have approved OraFID® for use
with a medicinal product.

"OraFID® is a unique, fully mechanical medical device that dispenses precise
quantities of minitablets to patients. It enables personalized, fine-tuned
treatment with minitablets, and I am thrilled to see the approval of this
important milestone." says Kathrine Gamborg Andreassen, Chief Executive Officer
of Navamedic.

Treatments with a narrow therapeutic window can benefit from hyper-fractioning
of the dose, by dividing it into minitablets, each containing a fraction of the
dose.

OraFID® works with a couple of twists of the hands and ejects an exact number of
minitablets.
It is approved as an integral combination product for Flexilev®, Navamedic's
medication for the treatment of Parkinson's.

The launch in Nordic markets is anticipated in October 2025.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail:
kathrine@navamedic.com

Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: Lars.Hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.

For more information, please visit Navamedic.com